Catheter Precision, Inc. · AMEX:VTAK
Catheter Precision — Ra Medical Systems — Investor Presentation (December 2019)
25 slides from Catheter Precision's investor presentation, Dec 11, 2019
Slide 1: Ra Medical Systems, Inc.
Exhibit 99.1 WL Ra Medical’ SYSTEMS Ra Medical Systems, Inc. NYSE: RMED DECEMBER 11, 2019
Slide 2: Disclaimer
Disclaimer , Inc. (the “Company”) , uncertainties and other factors t results, levels of activity, statements. n some cases, forward-looking statements can be identified by terminology such as “may,” ‘wil “could,” “would” “should, “expect.” “plan,” “anticipate,” Sioa ere cecilia ei tea ot i coveraie
Slide 3: Ra Medical Snapshot
Ra Medical Snapshot DABRA—Excimer laser that utilizes disposable catheters for crossing total chronic occlusions (CTOs) and ablating a channel in occlusive peripheral vascular disease. DABRA is used as a tool to treat peripheral artery disease (PAD), a form of peripheral vascular disease. Photo abla
Slide 4: Highlights
Highlights Existing US Reimbursement Structure Time Efficient and Easy-to-Use Solution $1.08B+ Targeted US Annual TAM Among “17.6M PAD Sufferers in the US Single-Use Catheters Highly Experienced Leadership Ra Medical
Slide 5: Peripheral Artery Disease
Peripheral Artery Disease Only 20 to 30% of peripheral artery disease patients are actively being treated Disease Overview f the lower ly in the legs ‘Smoking, genetic predisposition, diabetes, age and obesity may increase risk Characterized by reduced blood flow to surrounding tissue If untreated c
Slide 6: Current Treatments and Limitations
Current Treatments and Limitations Non-Invasive Management Interventional Procedures Lifestyle Changes * Often hard to sustain and do not treat underlying cause of disease Pharmacotherapy * Generally prescribed for life and do not treat the obstruction, making ny them ineffective for mai + More aggr
Slide 7: DABRA Technology and Mechanism of Action
DABRA Technology and Mechanism of Action DABRA Technology Plaque Removal Process + 308 nanometer excimer laser system . ie ; Crosses through Unique liquid-illed, full aperture ratio catheter a Improves blood lesions * High quality lumen * Minimizes mechanical or thermal trauma Mechanism of Action *
Slide 8: Our Solution: DABRA
Our Solution: DABRA maa | “a * Can cross and de-bulk wide variety of plaque . — Soft thrombus to hard calcified plaque * Tool used by physicians to treat Chronic Total . Occlusions (CTOs) prior to other alternative . treatments * Ability to use Above-the-Knee (ATK) and Below-the- ee (BTK) * Monother
Slide 9: Clinically Demonstrated Solutions
Clinically Demonstrated Solutions Pivotal Study DABRA Effectiveness + Multi-site study at four sites in US and Mexico _ + Enrolled 64 patients with target blockage refractory to 100 92% guidewire crossing 90 Primary Efficacy Endpoint: ss + Successful crossing of target lesion based on angiographic a
Slide 10: Large US Addressable Market Opportunity
Large US Addressable Market Opportunity Potential Future Growth Applications KEY DRIVER Current US Market Opportunity (Not FDA approved) ion PAD Sufferers in the US Coronary Other peers: Artery Vascular 2: 2 i aitae Disease Occlusions Only 20-30% of PAD Patients actively treated Annual US Total Addr
Slide 11: Payors and Reimbursement
Payors and Reimbursement Approvals / Clearances * DABRA: US FDA 510(k), CE Mark * PHAROS: US FDA 510(k), CE Mark, CFDA, KFDA Payor Coverage Medi other third- . claims for ically submitted by provi party payors using established Current Procedural Terminology (CPT) codes * Pharos treatments are reimb
Slide 12: Physician Practice Needs
Physician Practice Needs Established ‘li Versatility Safety and i Able to cross and Efficacy om We believe our solution expands provider economics “Ra Medical
Slide 13: Competitive Positioning
Competitive Positioning Cardiovascular Spectranetics Medtronic/Covidien | Boston Scientific $ Debulking Not effective for hard -apabili Hard plaque only plaque Able to Cross x v x v a cto? We believe our solution compares favorably on numerous metrics against est ed competition "Ra Medical ESI
Slide 14: Pharos Excimer Laser
Pharos Excimer Laser Used by Physicians to Treat Chronic Skin Diseases surface of the skin causing scales and red patches + Vitilig the skit i th pigment from . 7 ie RTE: rch SAMA ced d ski T-cell lymphoma (CTCL) Market Opportunity for Chronic Skin Disease + Psoriasis, vitil i it + Psoriasis affects
Slide 15: Pharos Science, Advantages and Reimbursement
Pharos Science, Advantages and Reimbursement Pharos Science * Same laser platform as DABRA. * 308-1 laser—the center of acti for most it diated i disea: * Does not use heat or ablate lesi painle: . i jimi Bi y di tissue, sparing healthy skin from exposure * Delivers uniform dosing for optimal result
Slide 16: Carlsbad, CA
= Carlsbad, CA I Fully Operational Manufacturing Facility Sizable capacity for laser and catheter production AS ca (Ca ie CA wh sires orale facility fully staffed and operational Existing facility expected to be capable of manufacturing > 400 lasers/year and 140,000 catheters/year Fully capitalized
Slide 17: Pipeline Indications (Not FDA Approved)
Pipeline Indications (Not FDA Approved?) BRA (Vascular) PHAROS (Dermatology) eer Cutaneous T-Cell lymphoma (CTCL) : prot \ “4 iT tent Resteno: “Ra Medical Ez Other Vascular Occli s
Slide 18: Intellectual Property Portfolio
Intellectual Property Portfolio — ° Th i i is ad 1 inventio b ,, and as such, has filed patent applications directed to innovative methods and apparatus patents + Issued patents as of December 6, 2019: 5 US / 2 0US PatentiFile No Filing Date Country Status Small flexible liquid core catheter for las
Slide 19: Executive Team and Board of Directors
Executive Team and Board of Directors Martin Colombatto ——a Andrew Jack Interim CEO Maurice Buchbinder, MD Master Jeffrey Kraws President William Enquist Comer Cations tee Dan Horwood General Counsel and Secretary Richard Mejia Former Partner of Ernst & Young Mark Saad Cytori Therapeutics and former
Slide 20: Ra Medical Systems
WL Ra Medical’ SYSTEMS
Slide 21: Business Model
Business Model Laser Module DABRA™ Catheter Consumable Capital Placement and Sale Recurring Revenue —
Slide 22: Results of Operations
Results of Operations (into Vascular Net Revenue qi Dermatology Net Revenue ines $4,688 Operating Expenses: Selling, General and Administrative $15,889 $42,907 (Incl. $6.6M and $19.3M stock comp exp.) Research and Development $1,182 $3,692 (Incl. $0.3M and $1.4M stock comp exp.) Total Operating Expe
Slide 23: Financial Position
Financial Position (S in thousands) As of Sept. 30, 2019 Cash and Cash Equivalents and Short Term $40,476 Investments Working Capital? $37,470 Total Assets $54,002 Equipment Financing $783 Accumulated Deficit $(107,414) Total Stockholders’ Equity $41,741 1) We defin ki ital as current i liabilities
Slide 24: Milestones
ee Milestones * 3Q18—-IPO * 1Q19-Started Registry to study the benefit and safety profile of DABRA over a two-year term 2Q19 — Hired VP Quality, Regulatory and Clinical Affairs 3Q19 — Launched Pharos, Optimized 3Q19 — Received FDA approval for IDE to initiate atherectomy clinical trial 1Q20 — Initia
Slide 25: Highlights
Highlights Existing US Reimbursement Structure Time Efficient and Easy-to-Use Solution $1.08B+ Targeted US Annual TAM Among “17.6M PAD Sufferers in the US Single-Use Catheters Highly Experienced Leadership Ra Medical
Ra Medical Systems — Investor Presentation (December 2019) on 6ix